Close Menu
    What's Hot

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Andela is Named a Select Tier Services Partner in the Claude Partner Network

    November 18, 2026
    Facebook X (Twitter) Instagram
    Trending
    • Botswana reviews proposed 33% power tariff hike today
    • PM Modi meets Prince and Princess of Wales in New Delhi
    • Andela is Named a Select Tier Services Partner in the Claude Partner Network
    • Petrol price jump lifts South Africa inflation as SARB weighs rates
    • DXB handles 50.4 million passengers in first nine months
    • Congo Ebola death toll reaches 5,568 as cases pass 11,000
    • ASEAN signs digital economy pact eyeing $2 trillion by 2030
    • Tüyap highlights MENA sourcing opportunities at the carpet expo in Istanbul
    • Home
    • Contact Us
    Tripoli UpdateTripoli Update
    Friday, November 20
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Tripoli UpdateTripoli Update
    Home » HIV prevention gains boost with EU nod for twice-a-year shot

    HIV prevention gains boost with EU nod for twice-a-year shot

    July 28, 2025 Health

    The European Medicines Agency (EMA) has issued a positive recommendation for the authorization of lenacapavir, a twice-yearly injectable medication for HIV prevention. Marketed in Europe under the name Yeytuo by Gilead Sciences, the drug is now positioned for formal approval by the European Commission, which would allow its use across all 27 European Union member states, along with Iceland, Norway and Liechtenstein.

    Lenacapavir is a pre-exposure prophylaxis (PrEP) medication that has demonstrated near-total effectiveness in preventing HIV transmission. In two large Phase 3 clinical trials, PURPOSE 1 and PURPOSE 2, the drug was found to be 100 percent effective among women in sub-Saharan Africa and 99.9 percent effective among men and gender-diverse individuals in multiple countries, including Argentina, Thailand and the United States.

    The twice-yearly injection is the longest-acting PrEP option to date, offering a practical alternative to daily oral medications and existing injectable therapies administered every two months. The EMA’s Committee for Medicinal Products for Human Use reviewed the medication under an accelerated process, citing its major public health relevance. Public health officials and global health organizations have emphasized the significance of lenacapavir in the broader strategy to halt HIV transmission.

    Global health officials call for equitable access to lenacapavir

    The World Health Organization (WHO) recently recommended lenacapavir as an additional option for individuals at high risk of acquiring HIV. The United States Food and Drug Administration approved the same drug for prevention use in June. Despite significant advances in prevention, challenges remain. PrEP uptake is often hampered by stigma, limited access to healthcare and the need for strict adherence to daily regimens.

    Experts believe that lenacapavir’s long-acting nature can help reduce these barriers. Winnie Byanyima, executive director of the Joint United Nations Programme on HIV/AIDS (UNAIDS), has previously described lenacapavir as potentially transformative for global HIV prevention efforts, urging equitable distribution. Concerns have also been raised regarding the accessibility of the drug. Although Gilead has entered licensing agreements to allow generic production in 120 low-income countries, regions such as Latin America, where HIV incidence is rising, are largely excluded.

    High price and limited access spark global distribution concerns

    The medication currently sells for more than $28,000 annually in the United States, raising questions about affordability in middle-income countries. The EMA also assessed lenacapavir through its EU-M4All program, which enables faster regulatory approvals in collaboration with the WHO for nations outside the European Union. This approach is intended to improve access in countries with high unmet medical needs.

    According to the latest UNAIDS data, an estimated 40 million people are living with HIV globally, and approximately 630,000 individuals died from AIDS-related illnesses in 2024. As public health agencies and advocacy groups push for expanded access, lenacapavir is being viewed as a critical tool in the international effort to end HIV transmission by 2030. – By Content Syndication Services.

    Keep Reading

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    Africa CDC says Congo Ebola outbreak still not under control

    WHO reports 67 yellow fever cases in nine African countries

    Bangladesh dengue deaths reach 418 after deadliest month of 2026

    DR Congo Ebola cases top 10,000 in fastest-growing outbreak

    Zambezi Region records 33,944 malaria cases since January

    Latest News

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Petrol price jump lifts South Africa inflation as SARB weighs rates

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026

    ASEAN signs digital economy pact eyeing $2 trillion by 2030

    November 18, 2026

    Tunisia tourism revenues top $2.38 billion by end-October

    November 17, 2026

    Strong bookings push Etihad Calgary flights to daily service

    November 17, 2026
    © 2026 Tripoli Update | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.